



СРПСКИ АРХИВ
ЗА ЦЕЛОКУПНО ЛЕКАРСТВО
SERBIAN ARCHIVES
OF MEDICINE

Address: 1 Kraljice Natalije Street, Belgrade 11000, Serbia

+381 11 4092 776, Fax: +381 11 3348 653

E-mail: office@srpskiarhiv.rs, Web address: www.srpskiarhiv.rs

Paper Accepted*

ISSN Online 2406-0895

Case Report / Приказ болесника

Bilsana Mulić^{1,*}, Amira Peco Antić², Fatih Ozaltın³

Genotype/phenotype relationship in mild congenital nephrotic syndrome

Однос између генотипа и фенотипа у благом конгениталном нефротском синдрому

¹Novi Pazar General Hospital, Pediatric Department, Novi Pazar, Serbia;

²Acibadem BelMedic, Belgrade, Serbia;

³Hacettepe University, Faculty of Medicine, Department of Pediatric Nephrology, Ankara, Türkiye

Received: November 4, 2022

Accepted: December 20, 2023

Online First: January 12, 2024

DOI: <https://doi.org/10.2298/SARH221104007M>

* **Accepted papers** are articles in press that have gone through due peer review process and have been accepted for publication by the Editorial Board of the *Serbian Archives of Medicine*. They have not yet been copy-edited and/or formatted in the publication house style, and the text may be changed before the final publication.

Although accepted papers do not yet have all the accompanying bibliographic details available, they can already be cited using the year of online publication and the DOI, as follows: the author's last name and initial of the first name, article title, journal title, online first publication month and year, and the DOI; e.g.: Petrović P, Jovanović J. The title of the article. Srp Arh Celok Lek. Online First, February 2017.

When the final article is assigned to volumes/issues of the journal, the Article in Press version will be removed and the final version will appear in the associated published volumes/issues of the journal. The date the article was made available online first will be carried over.

***Correspondence to:**

Bilsana MULIĆ

Novi Pazar General Hospital, Pediatric Department, Generala Živkovića 1, 36300 Novi Pazar, Serbia

E mail: emmulić@mts.rs

Genotype/phenotype relationship in mild congenital nephrotic syndrome

Однос између генотипа и фенотипа у благом конгениталном нефротском синдрому

SUMMARY

Introduction Congenital nephrotic syndrome (CNS) is a severe disease complicated by hemodynamic instability, infections, thrombosis, growth disorder and progressive renal failure leading to end-stage kidney disease (ESRD) within a few years. The mutations of *NPHS1* encoding nephrin is the most common cause of the CNS.

The aim of this paper was to present a patient with *NPHS1* homozygous Ser350Pro missense mutation that unexpectedly caused a mild clinical course of CNS.

Case outline The patient is a girl who was diagnosed with severe nephrotic syndrome at 2.5 months of age. While waiting for the result of the genetic analysis, she was treated unsuccessfully with corticosteroids and angiotensin converting inhibitor (ACEI) four weeks, and then under Cyclosporine A (CsA) and ACEI she achieved partial remission within three months. Initially, the milder clinical course was explained by the positive effect of CsA, but as partial remission persisted even after the discontinuation of this drug, it remains unclear what influenced the improvement of the clinical course of the disease. At the time of writing this paper, the patient was 10.9 years old with normal serum creatinine, normal blood pressure and non-nephrotic proteinuria.

Conclusion *NPHS1* homozygous Ser350Pro missense mutation may be presented by a mild clinical course of CNS. Further studies are needed to clarify a more predictive CNS genotype/phenotype relationship.

Keywords: *NPHS1* gene; nephrin; hereditary nephrotic syndrome; infant

САЖЕТАК

Увод Конгенитални нефротски синдром (КНС) је тешка болест компликована хемодинамском нестабилношћу, инфекцијама, тромбозом, поремећајем раста и прогресијом бубрежне инсуфицијенције до терминалног стадијума (ТБИ) у року од неколико година. Мутације *NPHS1* који кодирају нефрин су најчешћи узрок КНС-а.

Циљ овог рада је да опишемо пацијента са хомозиготном *NPHS1 Ser350Pro missense* мутацијом која је неочекивано изазвала благи клинички ток КНС-а.

Приказ болесника Приказан је случај девојчице којој је са 2,5 месеца дијагностикован тешки нефротски синдром. Док је чекала резултат генетичке анализе, девојчица је четири недеље безуспешно лечена кортикостероидима и инхибитором ангиотензин конвертирајућег ензима (ACEI), а затим је под циклоспорином А (CsA) и ACEI постигла делимичну ремисију у року од три месеца. У почетку се блажи клинички ток објашњавао позитивним дејством циклоспорина, али како је делимична ремисија трајала и после укидања овог лека, остаје нејасно шта је утицало на побољшање клиничког тока болести. У време писања овог рада, пацијенткиња је имала 10,9 година, нормалан креатинин серума, нормалан крвни притисак и не-нефротску протеинурију.

Закључак *NPHS1* хомозиготна *Ser350Pro missense* мутација се може испољити благим клиничким током КНС. Потребне су даље студије да би се разјаснио предиктивни однос између генотипа и фенотипа у конгениталном нефротском синдрому.

Кључне речи: *NPHS1* ген; нефрин; херeditарни нефротски синдром; одојче

INTRODUCTION

Congenital nephrotic syndrome (CNS) is a heterogeneous group of disorder characterized by massive, nephrotic proteinuria, hypoalbuminemia, and edema, manifested in utero or during the first three months of life. CNS consequences are numerous including hemodynamic instability, infections, thrombosis, growth disorder and progressive renal failure leading to end-

stage renal disease (ESRD) usually in the early childhood [1].

In most cases the CNS is caused primarily by the underlying genetic abnormality related to structural and regulatory proteins of the glomerular filtration barrier [2, 3]. However, it can rarely be secondary, caused by congenital infections (syphilis, cytomegalovirus infection, toxoplasma, rubella, pertussis, immunodeficiency virus infection, malaria, hepatitis B) or due to immune disease of the mother [3–6].

Nowadays, genetic diagnosis of hereditary CNS is possible in 85%; More than 80% of genetic causes of CNS include mutations of the genes *NPHS1*, *NPHS2*, *WT1*, *PLCE1* and *LAMB2*, while other less commonly mutated genes account for an additional ~5% of CNS diagnoses [2]. The mutations of *NPHS1* or *NPHS2* are the most common causes of the CNS [2, 7]. An established genetic diagnosis of the CNS has a great influence on its management and prognosis. Since CNS is almost always a serious disease that is resistant to immunosuppressive therapy, management is very challenging and may require daily albumin infusions and intensive symptomatic treatments, but when optimal conservative measures are not successful to avoid complications, early unilateral or bilateral nephrectomy may be indicated [4]. Therefore, most children require renal replacement therapy in early childhood and the mortality rate is high [1, 4, 8]. However, although patients with CNS most often have an inevitable rapid progression to ESRD, extremely rare milder cases of the disease indicate that genetic diagnosis is not always reliable for predicting the clinical course of CNS [9, 10].

The aim of this report was to present our patient with *NPHS1* homozygote Ser350Pro missense mutation that unexpectedly manifested a mild clinical course. By this we wanted to point out the possible variations of the CNS genotype–phenotype relationship.

CASE REPORT

The patient is a girl who was diagnosed with severe nephrotic syndrome at 2.5 months

of age (Table 1). Her placenta was noticed to be enlarged. Parents denied consanguinity. An infectious or immunological etiology of the CNS was ruled out by appropriate investigations. A kidney biopsy was performed, which showed immature glomeruli with a mild degree of mesangial cell hypercellularity and microcystic dilatation of proximal tubules. A genetic analysis was requested abroad and homozygous *NPHS1* (NM_004646.4) c.1048T>C (p. Ser350Pro) missense mutation was reported. Due to hemodynamic instability caused by severe hypoalbuminemia, the patient required daily albumin infusions through a central venous catheter, which was changed several times due to infections. In addition, the patient received diuretics, vitamin D, thyroxin, and iron, as well as anticoagulants, gamma globulin replacement and antibiotics during frequent infections. Angiotensin-converting enzyme inhibitor (ACEI) was introduced into therapy in the third month of life, and corticosteroids from the seventh month for 4 weeks, without improvement of the disease. Cyclosporine A (CsA) treatment was then initiated with continuing ACEI, and partial remission was achieved within 3 months, together with resolving the need for albumin infusion. CsA and ACEI continued for the next four years. From the fourth to the ninth year of life, the girl was lost from medical follow-up because the situation in the family worsened due to the mother's illness (severe depression that required long-term hospital treatment), which most likely caused her not to receive regular medication, including CsA. At the most recent check-up, after the improvement of the mother's illness, the girl was 10,9 years old, body height was (BH) 125 cm (-2.85 z), body weight 28,5 kg (-1.36 z), BMI 18,2 kg/m² (0.37 z). Her short stature may not only be the result of a chronic disease, but also the influence of genetics, as both parents are short. She was normotensive, without edema. Her serum creatinine was normal as well as serum protein, and her proteinuria was in non-nephrotic range (416.8 mg/24h) (Table 1).

Ethical approval was granted by the local Ethics Committee of the General Hospital of Novi Pazar. The number of the ethical approval is 3498/2023. A signed, informed parenteral

consent was taken for publishing this report.

DISCUSSION

It is very well known, that an established genetic diagnosis of the CNS has a great influence on its management and prognosis; in genetic forms of CNS the use of immunosuppressive drugs should be avoided and renal biopsy is not necessary [4, 6]. However, the genetic diagnosis is not always able to reliably indicate the severity of the disease, which has a great impact on the treatment of the disease and its acceptance by the patient and parents. Variable disease penetrance can be a function of the specific mutation(s) involved or of allele dosage as well as the modulating influence of additional genetic variants but may also reflect the action of unlinked modifier genes, epigenetic changes or environmental factors [11].

While waiting for the genetic diagnosis, we tried treatment with corticosteroids without success, and then with CsA, during which a partial remission occurred and the need for albumin infusions ceased. The decision to introduce CsA in our patient was motivated by numerous problems in our patient related to daily intravenous albumin infusions, as well as reports on the favorable effect of CsA in hereditary nephrotic syndrome, which is explained by its ability to stabilize the actin cytoskeleton beyond its immunosuppressive effects [12-14]. In the previous report on our patient [15], the favorable course of the disease was mainly attributed to the effects of ACEI and CsA. However, since the patient was under very low and irregular doses of cyclosporine for the next six years, its influence on the course of the disease is not entirely clear. The antiproteinuric effect of ACEI cannot be underestimated but she received the drug in a small dose and probably irregularly. When everything is considered, it seems most likely that the *NPHS1* genetic disorder had the primary and decisive influence on the milder course of the disease in our patient. *NPHS1* gene is localized to chromosome 19q13.1 and encodes for nephrin protein, which is a fundamental constituent of the slit diaphragm, and plays a crucial

role in cell signaling [16]. Patrakka et al found that most *NPHS1* patients have the negative nephrin expression as well as the lack of slit diaphragm in kidneys that strongly indicate the total lack of functional nephrin in these patients causing massive proteinuria [17]. Only 1 out of 46 their patients with CNS had some nephrin expression retained in the kidneys associated with a mild CNS clinical course (Table 2). The authors suggested nephrin expression to be predictive for the favorable course of *NPHS1* disease [17]. This way of predicting the clinical course of the disease is generally not applied in clinical practice, and the findings of genetic analysis are mainly used. Table 2 presents other patients reported in the literature with a mild CNS clinical course. The homozygous missense mutation in exon 9 of the *NPHS1* gene designated as Ex9: c.1048T>C p. (Ser350Pro) was demonstrated in our patient. This mutation was first reported by Lenkkeri et al in 1999 [18]. To our knowledge, this homozygous mutation is not known to cause benign CNS except in our patient. Espinosa et al reported their patient who had spontaneous CNS remission at 6 months of age with an *NPHS* mutation identical to our patient (c.1048T>C (p. Ser350Pro) in exon 9) in one gene and different one in the other gene (c.3478C>T(p. Arg1160Ter) in exon 27) [19]. Wong et al performed *NPHS1* mutation analysis in 19 patients, five Caucasian patients and 14 Maori patients with a highly variable and protracted timeline to ESRD with median renal survival of 30 years versus 0.7 years in Caucasian patients [9]. Authors from China described complete remission of CNS under corticosteroid therapy in a girl who had heterozygous *NPHS1* mutation [20]. In Turkish study no association between the *NPHS1* mutation type (protein truncating or missense) and survival or age at diagnosis was found, but the patients with mutations affecting transmembrane or intracellular domains of nephrin in ≥ 1 alleles had a significantly longer survival time than patients with mutations affecting the extracellular domain in both alleles [7].

It can be concluded that *NPHS1* homozygous Ser350Pro missense mutation may be presented by a mild clinical course of CNS. More data are needed before the question of

phenotype/genotype correlations in CNS can be addressed.

Conflict of interest: None declared.

Paper accepted

REFERENCES

1. Hölttä T, Jalanko H. Congenital nephrotic syndrome: is early aggressive treatment needed? Yes. *Pediatr Nephrol.* 2020;35(10):1985–90. [DOI: 10.1007/s00467-020-04578] [PMID: 32377865]
2. Lipska-Ziętkiewicz BS, Ozaltin F, Hölttä T, Bockenhauer D, Bérody S, Levtschenko E, et al. Genetic aspects of congenital nephrotic syndrome: a consensus statement from the ERKNet-ESPN inherited glomerulopathy working group. *Eur J Hum Genet.* 2020;28(10):1368–78. [DOI: 10.1038/s41431-020-0642-8] [PMID: 32467597]
3. Peco Antić A. Kongenitalni nefrotski sindrom. U: *Glomerulske dečje bolesti*. Izdavač Peco Antić A, 2021, Beograd, Digital Art Company (ISBN 978-86.903440-0-0), str 111–34.
4. Boyer O, Schaefer F, Haffner D, Bockenhauer D, Hölttä T, Bérody S, et al. Management of congenital nephrotic syndrome: consensus recommendations of the ERKNet-ESPN Working Group. *Nat Rev Nephrol.* 2021;17(4):277–89. [DOI: 10.1038/s41581-020-00384-1]
5. Kouli A, Trab SS, Alshaghel S, Mouti MB, Hamdoun H. Congenital nephrotic syndrome as a complication of whooping cough: a case report. *Oxf Med Case Reports.* 2020;2020(2): omaa007. [DOI: 10.1093/omcr/omaa007] [PMID: 32128219]
6. Vivarelli M, Gibson K, Sinha A, Boyer O. Childhood nephrotic syndrome. *Lancet.* 2023;402(10404):809–24. [DOI: 10.1016/S0140-6736(23)01051-6]
7. Cil O, Besbas N, Duzova A, Topaloglu R, Peco-Antić A, Korkmaz E, et al. Genetic abnormalities and prognosis in patients with congenital and infantile nephrotic syndrome. *Pediatr Nephrol.* 2015;30(8):1279–87. [DOI: 10.1007/s00467-015-3058-x] [PMID: 25720465]
8. Bérody S, Heidet L, Gribouval O, Harambat J, Niaudet P, Baudouin V, et al. Treatment and outcome of congenital nephrotic syndrome. *Nephrol Dial Transplant.* 2019; 34:458–67. [DOI: 10.1093/ndt/gfy015] [PMID: 29474669]
9. Wong W, Morris MC, Kara T. Congenital nephrotic syndrome with prolonged renal survival without renal replacement therapy. *Pediatr Nephrol.* 2013;28(12):2313–21. [DOI: 10.1007/s00467-013-2584-7] [PMID: 23949594]
10. Rong L, Chen L, Rao J, Shen Q, Li G, Liu J, et al. Genetic Variations and Clinical Features of NPHS1-Related Nephrotic Syndrome in Chinese Children: A Multicenter, Retrospective Study. *Front Med (Lausanne).* 2021; 8:771227. [DOI: 10.3389/fmed.2021.771227] [PMID: 34859019]
11. Cooper DN, Krawczak M, Polychronakos C, Tyler-Smith C, Kehrer-Sawatzki H. Where genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetrance in human inherited disease. *Hum Genet.* 2013;132(10):1077–130. [DOI: 10.1007/s00439-013-1331-2] [PMID: 23820649]
12. Lee JM, Kronbichler A, Shin JJ, Oh J. Current understandings in treating children with steroid-resistant nephrotic syndrome. *Pediatr Nephrol.* 2021;36(4):747–61. [DOI: 10.1007/s00467-020-04476-9] [PMID: 32086590]
13. Kemper MJ, Lemke A. Treatment of Genetic Forms of Nephrotic Syndrome. *Front Pediatr.* 2018; 6:72. [DOI: 10.3389/fped.2018.00072] [PMID: 29632851]
14. Eichinger A, Ponsel S, Bergmann C, Günthner R, Hoefele J, Amann K, et al. Cyclosporine A responsive congenital nephrotic syndrome with single heterozygous variants in NPHS1, NPHS2, and PLCE1. *Pediatr Nephrol.* 2018;33(7):1269–72. [DOI: 10.1007/s00467-018-3961-z]
15. Mulić B, Miloševski-Lomić G, Paripović D, Kruščić D, Mulić M, Peco-Antić A. Congenital nephrotic syndrome may respond to cyclosporine A – A case report and review of literature. *Srpski arhiv za celokupno lekarstvo.* 2017; 145:407–10. [DOI: 10.2298/SARH160907070M]
16. Kestilä M, Männikkö M, Holmberg C, Gyapay G, Weissenbach J, Savolainen ER, et al. Congenital nephrotic syndrome of the Finnish type maps to the long arm of chromosome 19. *Am J Hum Genet.* 1994;54(5):757–64. [PMID: 8178817]
17. Patrakka J, Kestilä M, Wartiovaara J, Ruotsalainen V, Tissari P, Lenkkeri U, et al. Congenital nephrotic syndrome (NPHS1): features resulting from different mutations in Finnish patients. *Kidney Int.* 2000;58(3):972–80. [DOI: 10.1046/j.1523-1755.2000.00254.x] [PMID: 10972661]
18. Lenkkeri U, Männikkö M, McCready P, Lamerdin J, Gribouval O, Niaudet PM, et al. Structure of the gene for congenital nephrotic syndrome of the finnish type (NPHS1) and characterization of mutations. *Am J Hum Genet.* 1999;64(1):51–61. [DOI: 10.1086/302182] [PMID: 9915943]
19. Espinosa LG, Santoveña AZ, Blanco JN, Alvarino MG, Feito JB, Hijosa MM. Spontaneous remission in a child with an NPHS1-based congenital nephrotic syndrome. *Clin Kidney J.* 2022; 15: 1969–70. [DOI: 10.1093/ckj/sfac086]
20. Li Z, Zhuang L, Han M, Li F. A case report of congenital nephrotic syndrome caused by new mutations of NPHS1. *J Int Med Res.* 2021;49(8):3000605211038133. [DOI: 10.1177/03000605211038133] [PMID: 34396835]

Table 1. Trends of renal function, serum protein, proteinuria and therapy over time

Age (months)	sCr (μmol/l)	eGFR (ml/min./1.73 m ²)	serum albumin (g/l)	serum protein (g/l)	Urine protein/creatinine (mg/mg)	Daily iv albumin	Captopril (mg/kg BW/day)	CsA** (mg/kgBW/day)
2.5	15	134.7	9	37	28.2	-	-	-
7.3	25	100.8	37	62	32.8	12 g / 24 h	0.4	-
9	28	95	26	55	33	12 g / 24 h	0.4	6.2*
10.5	35–40	76.6	31	60	3.6	12 g / 24 h	0.6	5.8
12	33–83	84.8	31	63	5	-	0.9	4.5
18	26	139.4	23	55	3.6	-	0.7	4.6
20.5	25–40	148	18	53	4.9	-	0.9	7.2
24	21	184.3	18	51	4.9	-	1.2	6.6
30	27	153.3	18	54	4	-	1.2	6.6
42	43–45	103.7	-	-	-	-	5.4	-
57.5	16	306.2	19	56	3.2	-	0.9	4.3
Lost to follow-up								
9 years	45	136	33	65	1.5	-	0.5	?
10.5 years	39.9	180	30	63	1.5	-	0.3	-
10.9 years	31	197	32	66	1.45	-	0.3	-

sCr – serum creatinine; eGFR – estimated glomerular filtration rate; iv – intravenous; BW – body weight; CsA – cyclosporine A; **therapy started at the age of eight months

Table 2. Clinical and genetic characteristics of the *NPHS1* patients with mild congenital nephrotic syndrome course

Reference	Age at onset	Mutation in <i>NPHS1</i>	Clinical course	Treatment
8	No data	c.2131C > A(p.Arg711ser) homozygous missense mutation	Renal survival of 30 years	No data
16	After birth	Fin-major mutation in one gene and a missense mutation (a change of arginine-743 to cysteine in the extracellular Ig-5 domain) in the other one.	Partial remission	Indomethacin and Enalapril started at three months of age
18	11 days	Compound heterozygous for two different sequence variants in exons 9 and 27 (NM_004646.4:c.1048T>C:p.Ser350Pro; M_004646.4:c.3478C>T:p.Arg1160Ter)	Remission at six months	Supportive
19	No data	c.3478 C > T in exon 27 homozygous missense mutation	Remission at 11 years of age	No data
20	50 days	c.3312-23C > T intron 25 c.2207T > C exon 16 c.928G > A in exon 8	Remission	Glucocorticoids
Our case	2.5 months	Ex9: c.1048T > C p. (Ser350Pro)	Partial remission at 12 months	CsA + ACEI during four years